Per Lundkvist

Per Lundkvist

Auto-generated profile, based on publicly available information

Per Lundkvist

Department of Medical Sciences Uppsala University Uppsala Sweden

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
PKPetros Katsogiannos
Petros Katsogiannos
PKPrasad G Kamble
Prasad G Kamble
GBGretha J Boersma
Gretha J Boersma
FKF Anders Karlsson
F Anders Karlsson
PLPer Lundkvist
Per Lundkvist
Jan W. ErikssonJan W. Eriksson
Jan W. Eriksson
Context Roux-en-Y gastric bypass (RYGB) surgery effectively prevents or treats type 2 diabetes (T2D). Adipose tissue (AT) mechanisms may be of importance. Objective To assess the relationship between early changes in whole-body and AT metabolism in surgically treated patients with T2D. Design and Setting A randomized single-center study. Patients Nineteen patients with T2D with body mass index 30 to 45 kg/m2. Interventions Thirteen patients were assessed at baseline and 4 and 24 weeks after RYGB (preceded by a 4-week low-calorie diet) and compared with 6 control patients continuing standard medical treatment: oral glucose tolerance test, subcutaneous AT biopsies for gene expression, adipocyte size, glucose uptake, lipolysis, and insulin action. Results At 4 and 24 weeks post-RYGB, all patients but one had stopped diabetes medication. Fasting glucose, HbA1c, and insulin levels decreased and the Matsuda index increased compared with baseline (P < 0.01 for all), indicating improved whole-body insulin sensitivity. Mean adipocyte size significantly reduced, more at 4 than at 24 weeks; at 4 weeks, glucose uptake per adipocyte was lowered, and isoproterenol-stimulated lipolysis tended to increase, whereas the fold insulin effects on glucose uptake and lipolysis were unchanged. Expression of genes involved in fatty acid oxidation, CPT1b and adiponectin, was increased at 4 weeks, whereas leptin and E2F1 (involved in cell proliferation) were reduced (P < 0.05 for all). Conclusion Glycemic control and in vivo insulin sensitivity improved 4 weeks after RYGB, but adipocyte insulin sensitivity did not change despite a marked reduction in adipocyte size. Thus, mechanisms for a rapid improvement of T2D after RYGB may occur mainly in other tissues than adipose.

17 August 2018 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
PLPer Lundkvist
Per Lundkvist
MPMaria Pereira
Maria Pereira
PKPrasad G Kamble
Prasad G Kamble
PKPetros Katsogiannos
Petros Katsogiannos
ALAnna Maria Langkilde
Anna Maria Langkilde
Jan W. ErikssonJan W. Eriksson
Jan W. Eriksson
Context Sodium glucose cotransporter-2 (SGLT2) inhibitors can raise glucagon levels, but whether this is mediated via direct effects on islet cells or indirectly via blood glucose lowering is unknown. Objective To assess short-term effects on glucagon and other hormones as well as energy substrates following SGLT2 inhibition and whether such effects are secondary to glucose lowering. Moreover, the impact of adding a dipeptidyl peptidase-4 inhibitor was addressed. Design and Setting A phase IV, single-center, randomized 3-treatment crossover, open-label study. Patients 15 metformin-treated type 2 diabetes patients. Interventions At the three visits patients received a single-dose of dapagliflozin 10mg accompanied by either of the following in randomized order: isoglycemic clamp (experiment DG); saline infusion (experiment D); or saxagliptin 5mg plus saline infusion (experiment DS). Directly after 5-h infusion periods, a 2-h oral glucose tolerance test (OGTT) was performed. Results Glucose and insulin levels were stable in experiment DG and decreased in experiment D (Pdiff <0.001). Glucagon (Pdiff <0.01), glucagon/insulin ratio (Pdiff <0.001), non-esterified fatty acids (Pdiff <0.01), glycerol (Pdiff <0.01) and β-OH-butyrate (Pdiff <0.05) were all lower in DG vs D. In multivariate analysis, change in glucose level was the main predictor of change in glucagon level. In DS, glucagon and active GLP-1 were higher vs D but glucose and insulin did not differ. During OGTT, DS had less glucose rise and greater glucagon fall vs D. Conclusion The degree of glucose lowering markedly contributes to regulation of glucagon and insulin secretion as well as lipid mobilization during short-term SGLT2 inhibition.

27 February 2024 in BMJ Open Diabetes Research & Care
Verified
Journal Article
Open access
PDF file
PLPer Lundkvist
Per Lundkvist
AGAnnika Grönberg
Annika Grönberg
PCPer-Ola Carlsson
Per-Ola Carlsson
JLJohnny Ludvigsson
Johnny Ludvigsson
DEDaniel Espes
Daniel Espes
Introduction The rate of progression to complete insulin deficiency varies greatly in type 1 diabetes. This constitutes a challenge, especially when randomizing patients in intervention trials aiming to preserve beta cell function. This study aimed to identify biomarkers predictive of either a rapid or slow disease progression in children with new-onset type 1 diabetes. Research design and methods A retrospective, longitudinal cohort study of children (<18 years) with type 1 diabetes (N=46) was included at diagnosis and followed until complete insulinopenia (C-peptide <0.03 nmol/L). Children were grouped into rapid progressors (n=20, loss within 30 months) and slow progressors (n=26). A sex-matched control group of healthy children (N=45) of similar age was included for comparison. Multiple biomarkers were assessed by proximity extension assay (PEA) at baseline and follow-up. Results At baseline, rapid progressors had lower C-peptide and higher autoantibody levels than slow. Three biomarkers were higher in the rapid group: carbonic anhydrase 9, corticosteroid 11-beta-dehydrogenase isozyme 1, and tumor necrosis factor receptor superfamily member 21. In a linear mixed model, 25 proteins changed over time, irrespective of group. One protein, a coxsackievirus B–adenovirus receptor (CAR) increased over time in rapid progressors. Eighty-one proteins differed between type 1 diabetes and healthy controls. Principal component analysis could not distinguish between rapid, slow, and healthy controls. Conclusions Despite differences in individual proteins, the combination of multiple biomarkers analyzed by PEA could not distinguish the rate of progression in children with new-onset type 1 diabetes. Only one marker was altered significantly when considering both time and group effects, namely CAR, which increased significantly over time in the rapid group. Nevertheless, we did find some markers that may be useful in predicting the decline of the C-peptide. Moreover, these could potentially be important for understanding type 1 diabetes pathogenesis.

3 December 2025 in JIMD Reports
Verified
Journal Article
Open access
PLPer Lundkvist
Per Lundkvist
KMKarin Blom Malmberg
Karin Blom Malmberg
LLLinda Lindström
Linda Lindström
AKAndreas Kindmark
Andreas Kindmark
Phenylketonuria (PKU) is an autosomal recessive disorder caused by a deficiency of phenylalanine hydroxylase (PAH), leading to the accumulation of phenylalanine (Phe) and an increased risk of developmental disorders. Treatment involves a Phe‐restricted diet, amino acid supplements, and for a subset of patients, a tetrahydrobiopterin (BH4) chaperone. Managing PKU during pregnancy is challenging due to changing protein and energy needs, stricter Phe control, nausea, and unpalatable supplements. In rare cases of simultaneous maternal and fetal PKU, Phe tolerance may increase less throughout gestation, raising the demands on the patient and caregivers. There are few reports and no guidelines on the management of PKU during pregnancies in which both mother and fetus have PKU, hereafter referred to as maternal‐fetal PKU (mfPKU). This report outlines our approach for successfully managing two consecutive mfPKU pregnancies. We emphasize a patient‐centered approach, focusing on patient education and close collaboration with a multidisciplinary metabolic team. This involves regular monitoring of body weight, blood Phe levels, and calorie intake through an online food diary to tailor individual recommendations for natural protein restriction and amino acid supplements.

13 August 2026 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
JCJosé Caballero‐Corbalán
José Caballero‐Corbalán
PLPer Lundkvist
Per Lundkvist
DEDaniel Espes
Daniel Espes
PCPer‐Ola Carlsson
Per‐Ola Carlsson
Aims: To evaluate the effect of liraglutide on residual beta‐cell function in adults with long‐standing type 1 diabetes (T1D) and detectable C‐peptide. Materials and Methods: In this randomized, blinded, placebo‐controlled trial, 18 adults with T1D duration ≥ 5 years and detectable fasting C‐peptide were assigned to liraglutide or placebo for 52 weeks. Mixed‐meal tolerance tests were performed at baseline and weeks 6, 52, and 65. The primary endpoint was change in stimulated C‐peptide area under the curve from baseline to week 52. Results: Liraglutide did not improve stimulated C‐peptide compared with placebo at week 52. In exploratory post hoc longitudinal analyses including the post‐treatment period (weeks 0–65), stimulated C‐peptide declined more steeply in the liraglutide group than in the placebo group, accompanied by increasing insulin requirements over time. Conclusions: In adults with long‐standing T1D, liraglutide did not preserve stimulated C‐peptide after 52 weeks. Exploratory post hoc longitudinal analyses suggested a steeper decline in stimulated C‐peptide with liraglutide than with placebo.

5 May 2017 in Diabetologie und Stoffwechsel
Verified
Journal Article
Closed access
PLP Lundkvist
P Lundkvist
SAS Amini
S Amini
JBJ Lau Börjesson
J Lau Börjesson
MPMj Pereira
Mj Pereira
PKP Kamble
P Kamble
CKC Klisch
C Klisch
Hintergrund: In einer verblindeten, placebokontrollierten Phase-2-Studie wurde Dapagliflozin (DAPA) in Kombination mit Exenatide (EXE) bei übergewichtigen Erwachsenen mit unauffälligem Glukosestoffwechsel, abnormer Nüchternglukose (IFG, Nüchternglukose ≥5,6 mmol/l) oder eingeschränkter Glukosetoleranz (IGT) untersucht. Eine stärkere Reduktion von Körpergewicht, vor allem durch Verlust von Fettgewebe, sowie von HbA1c und Nüchternglukose, des Anteils Patienten mit IFG bzw. IGT sowie der Glukose-AUC im OGTT wurde bereits auf dem ADA 2016 vorgestellt. Hier werden zusätzliche Ergebnisse präsentiert, die den Lipidstoffwechsel betreffen. Methodik: In einer monozentrischen, 1:1 randomisierten, 24-wöchigen, doppelblinden Studie erhielten 50 adipöse (BMI 30 – 45 kg/m2) Erwachsene ohne Diabetes zwischen 18 und 70 Jahren randomisiert entweder 10 mg/d DAPA und 2 mg/Woche EXE (n = 25) oder entsprechende Placebos (n = 25). Es wurden ein Ganzkörper-MRT erstellt und anthropometrische Daten, sowie Laborwerte nüchtern und zum Zeitpunkt 3 Stunden im oralen Glukosetoleranztest (oGTT) erfasst. Ergebnisse: Die AUC freier Fettsäuren (FFA) im oGTT nahm im Vergleich zum Ausgangswert unter DAPA+EXE um 19% zu, die AUCs von Insulin und Glycerol sowie ß-Hydroxyketone zeigten keine signifikanten Veränderungen. Insulinsekretion und Insulinsensitivität änderten sich ebenfalls nicht. In keiner Behandlungsgruppe änderten sich Triglyceride, Gesamtcholesterin, LDL-Cholesterin oder HDL-Cholesterin. Unerwünschte Ereignisse entsprechen den Nebenwirkungsprofilen der beiden Wirkstoffe. Schlussfolgerung: In dieser Phase-2-Studie mit adipösen Probanden ohne Diabetes führte die Kombinationstherapie mit DAPA+EXE gegenüber PBO zu einer signifikanten Reduktion von Gewicht, HbA1c und Glukosespiegel nach Provokation. IFG und IGT zeigten sich weitgehend normalisiert. Diese Wirkungen traten ohne signifikante Veränderungen der geschätzten Insulinsensitivität und der Betazellfunktion auf. Der FFA-Anstieg spricht möglicherweise für eine vermehrte Energiegewinnung aus Fettsäuren nach Lipidmobilisierung.